{Reference Type}: Journal Article
{Title}: Bacterial glycoengineering: Cell-based and cell-free routes for producing biopharmaceuticals with customized glycosylation.
{Author}: Palma JA;Bunyatov MI;Hulbert SW;Jewett MC;DeLisa MP;
{Journal}: Curr Opin Chem Biol
{Volume}: 81
{Issue}: 0
{Year}: 2024 Aug 10
{Factor}: 8.972
{DOI}: 10.1016/j.cbpa.2024.102500
{Abstract}: Glycosylation plays a pivotal role in tuning the folding and function of proteins. Because most human therapeutic proteins are glycosylated, understanding and controlling glycosylation is important for the design, optimization, and manufacture of biopharmaceuticals. Unfortunately, natural eukaryotic glycosylation pathways are complex and often produce heterogeneous glycan patterns, making the production of glycoproteins with chemically precise and homogeneous glycan structures difficult. To overcome these limitations, bacterial glycoengineering has emerged as a simple, cost-effective, and scalable approach to produce designer glycoprotein therapeutics and vaccines in which the glycan structures are engineered to reduce heterogeneity and improve biological and biophysical attributes of the protein. Here, we discuss recent advances in bacterial cell-based and cell-free glycoengineering that have enabled the production of biopharmaceutical glycoproteins with customized glycan structures.